Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
The ICR and The Royal Marsden team up with PureGym to support men with advanced prostate cancer to be more active
The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have teamed up with Sir Chris Hoy and PureGym to launch a collaboration to encourage men with prostate cancer to be more active.
Subtle chemical tweak helps determine whether cells grow, potentially affecting cancer risk
Researchers have discovered a tiny chemical switch inside our cells that helps control whether they keep dividing or stop for good – a finding that could influence future cancer therapies and deepen our understanding of ageing.
Postdoc Maria Taskinen wins ICR Science and Medical Image Competition 2025
Seven images were shortlisted for this year’s annual Science and Medical Image competition, showcasing the eye-catching science being carried out at the ICR. Three winners were selected by a judging panel and the fourth was chosen by the public based on votes on social media.
New research reveals how combining viruses with targeted drugs can boost cancer-killing immune responses
Two studies have uncovered how combining a cancer-killing reovirus with targeted cancer drugs can dramatically boost immune responses and tumour destruction – offering a promising route to more effective, personalised cancer therapies.